<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02281526</url>
  </required_header>
  <id_info>
    <org_study_id>BIA-2093-111</org_study_id>
    <nct_id>NCT02281526</nct_id>
  </id_info>
  <brief_title>An Open-label, Multiple-dose, Single-centre Study, Investigating the Pharmacokinetics of BIA 2-093</brief_title>
  <official_title>An Open-label, Multiple-dose, Single-centre Study, Investigating the Pharmacokinetics of BIA 2-093 in Subjects With Moderate Hepatic Impairment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bial - Portela C S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bial - Portela C S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open-label, multiple-dose, single-centre study in 2 groups of subjects: subjects with
      moderate hepatic impairment and healthy controls. The trial consisted of a screening visit, a
      treatment phase and a follow-up visit. All subjects were to be treated with study medication
      for 8 consecutive days. Blood and urine were collected for the PK analysis, and safety
      assessments were performed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The screening visit was performed 2 to 21 days before the first administration of study
      medication, the treatment phase consisted of 12 days (of which study medication was
      administered during the first 8 days), and the follow-up visit was performed 15 to 19 days
      after the first administration of study medication.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">February 2006</completion_date>
  <primary_completion_date type="Actual">February 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve, AUC(0-tlast).</measure>
    <time_frame>pre-dose and 1, 2, 2.5, 2.75, 3, 3.25, 3.5, 3.75, 4, 4.25, 4.5, 4.75, 5, 7, 9, 12 and 24 hours post-dose.</time_frame>
    <description>Day 1 - Area under the plasma concentration versus time curve, AUC(0-tlast).
BIA 2-194, 2-195 Glucoronide, Oxcarbazepine, BIA 2-093 Glucoronide, 2-194 Glucoronide are BIA 2-093 metabolites.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax - Peak Plasma Concentration</measure>
    <time_frame>pre-dose and 1, 2, 2.5, 2.75, 3, 3.25, 3.5, 3.75, 4, 4.25, 4.5, 4.75, 5, 7, 9, 12 and 24 hours post-dose.</time_frame>
    <description>Day 1 - Cmax Peak plasma concentration</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>Subjects with moderate hepatic impairment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>This was an open-label, multiple-dose, single-centre study in 2 groups of subjects: subjects with moderate hepatic impairment and healthy controls</description>
  </arm_group>
  <arm_group>
    <arm_group_label>subjects - healthy controls</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>This was an open-label, multiple-dose, single-centre study in 2 groups of subjects: subjects with moderate hepatic impairment and healthy controls</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIA 2-093</intervention_name>
    <arm_group_label>Subjects with moderate hepatic impairment</arm_group_label>
    <arm_group_label>subjects - healthy controls</arm_group_label>
    <other_name>Eslicarbazepine Acetate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females at least 18 years of age.

          -  Female subjects had to be post-menopausal, surgically sterilized or using a reliable
             non-hormonal method of contraception. Examples of reliable non-hormonal methods of
             contraception include tubal ligation, hysterectomy, intrauterine device, or a barrier
             method combined with a spermicide. Hormonal contraceptives were not allowed because
             the effect of BIA 2-093 on the metabolism of oral contraceptives was not yet known.

          -  Subjects suffering from a chronic illness, other than hepatic impairment, had to have
             a stable condition, regarded by the investigator as not able to influence the outcome
             of the study.

          -  For subjects to be included in Group 1, a stage of moderate hepatic impairment, the
             extent of which, as measured by the Child-Pugh classification, resulted in recruitment
             into the study (Group 1 only). This did not apply to subjects that were recruited into
             Group 2, whose liver functioning was to be normal.

          -  Body mass not less than 50 kg.

        Exclusion Criteria:

          -  The receipt of any investigational drug within the 30 days prior to this trial.

          -  Clinically significant abnormal findings (as judged by the investigator) for the
             following parameters, except those consistent with findings in hepatic impairment:
             haematology, biochemistry, clotting profile, urinalysis, vital signs or ECG screening
             tests.

          -  A history or laboratory evidence of renal impairment and/or disease. Owing to the
             metabolic pathway of BIA 2-093, any degree of renal impairment would have had a
             confounding effect on the PK analysis.

          -  Positive test for Human Immunodeficiency Virus (HIV)-1 or HIV-2 antibodies, Hepatitis
             B surface antigen and Hepatitis C antibodies. HIV positive patients, and patients with
             Hepatitis B and C, generally have a below average, and in some cases a markedly
             decreased, level of health owing to the nature of the respective infections and the
             natural course of the diseases, both of which are often complicated by an array of
             opportunistic illnesses. Their ill health would be further worsened by the fact that
             the patients are hepatically impaired, which has its own, often debilitating,
             complications. If patients with HIV or Hepatitis B or C were included in the study,
             this could have led to statistical confusion when assessing the safety and
             tolerability parameters. This is because events reported by the subjects, which might
             be a part of the spectrum of complaints in HIV positive patients and Hepatitis B and C
             patients, would confound the safety and tolerability analysis. In addition, by
             administering the study medication to these patients, any AEs that might have occurred
             would add to the discomfort of the patient.

          -  A history of any illness that, in the opinion of the investigator and/or sponsor,
             might confound the results of the study or pose additional risk in administering the
             investigational product to the subject.

          -  Any planned procedures and/or devices to be performed/added during the course of the
             study, which might influence the evaluation of the endpoints of the study.

          -  Current addiction to alcohol as determined by the investigator.

          -  Use of any medication, prescribed or over-the-counter, except drugs indicated for the
             treatment of concomitant illnesses in subjects with moderate hepatic impairment, or if
             the drugs would not have affected the outcome of the study in the opinion of the
             investigator. Vitamin use was allowed, but should have been stable during the course
             of the study.

          -  Current treatment with oxcarbazepine.

          -  Mental incapacity, unwillingness or language barriers precluding adequate
             understanding or cooperation.

          -  Subjects with a supine pulse rate at screening, after resting for 5 min, outside the
             range of 50 - 100 beats per minute (bpm).

          -  A history of multiple and/or severe allergies to drugs or foods or a history of
             anaphylactic reactions.

          -  Known or suspected allergy to trial product or related products (e.g carbamazepine or
             oxcarbazepine).

          -  Female subjects who were pregnant or lactating.

          -  Previous participation in (recruitment into) this trial.

          -  Donation or loss of blood equal to or exceeding 500 mL during the 8 weeks before dose
             administration.

          -  Any history of a bleeding tendency, or an active bleed in the preceding 3 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Farmovs-Parexel</name>
      <address>
        <city>Bloemfontein</city>
        <zip>9301</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 30, 2014</study_first_submitted>
  <study_first_submitted_qc>October 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2014</study_first_posted>
  <results_first_submitted>November 28, 2014</results_first_submitted>
  <results_first_submitted_qc>January 7, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 12, 2015</results_first_posted>
  <last_update_submitted>January 7, 2015</last_update_submitted>
  <last_update_submitted_qc>January 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eslicarbazepine acetate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Subjects With Moderate Hepatic Impairment</title>
          <description>This was an open-label, multiple-dose, single-centre study in 2 groups of subjects: subjects with moderate hepatic impairment and healthy controls
BIA 2-093</description>
        </group>
        <group group_id="P2">
          <title>Subjects - Healthy Controls</title>
          <description>This was an open-label, multiple-dose, single-centre study in 2 groups of subjects: subjects with moderate hepatic impairment and healthy controls
BIA 2-093</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Subjects With Moderate Hepatic Impairment</title>
          <description>This was an open-label, multiple-dose, single-centre study in 2 groups of subjects: subjects with moderate hepatic impairment and healthy controls
BIA 2-093</description>
        </group>
        <group group_id="B2">
          <title>Subjects - Healthy Controls</title>
          <description>This was an open-label, multiple-dose, single-centre study in 2 groups of subjects: subjects with moderate hepatic impairment and healthy controls
BIA 2-093</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="17"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration Versus Time Curve, AUC(0-tlast).</title>
        <description>Day 1 - Area under the plasma concentration versus time curve, AUC(0-tlast).
BIA 2-194, 2-195 Glucoronide, Oxcarbazepine, BIA 2-093 Glucoronide, 2-194 Glucoronide are BIA 2-093 metabolites.</description>
        <time_frame>pre-dose and 1, 2, 2.5, 2.75, 3, 3.25, 3.5, 3.75, 4, 4.25, 4.5, 4.75, 5, 7, 9, 12 and 24 hours post-dose.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Subjects With Moderate Hepatic Impairment</title>
            <description>This was an open-label, multiple-dose, single-centre study in 2 groups of subjects: subjects with moderate hepatic impairment and healthy controls
BIA 2-093</description>
          </group>
          <group group_id="O2">
            <title>Subjects - Healthy Controls</title>
            <description>This was an open-label, multiple-dose, single-centre study in 2 groups of subjects: subjects with moderate hepatic impairment and healthy controls
BIA 2-093</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration Versus Time Curve, AUC(0-tlast).</title>
          <description>Day 1 - Area under the plasma concentration versus time curve, AUC(0-tlast).
BIA 2-194, 2-195 Glucoronide, Oxcarbazepine, BIA 2-093 Glucoronide, 2-194 Glucoronide are BIA 2-093 metabolites.</description>
          <units>h·ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC(0-tlast) BIA 2-093</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="954.891" spread="963.751"/>
                    <measurement group_id="O2" value="49.750" spread="27.931"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC(0-tlast) BIA 2-194</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="240188.369" spread="27773.762"/>
                    <measurement group_id="O2" value="234750.429" spread="31036.558"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC(0-tlast) 2-195 Glucoronide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.603" spread="44.226"/>
                    <measurement group_id="O2" value="157.738" spread="199.859"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC(0-tlast) Oxcarbazepine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1489.530" spread="1055.930"/>
                    <measurement group_id="O2" value="1899.092" spread="915.761"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC(0-tlast) BIA 2-093 Glucoronide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.875" spread="2.312"/>
                    <measurement group_id="O2" value="2.500" spread="2.500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC(0-tlast) BIA 2-194 Glucoronide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8634.780" spread="5915.045"/>
                    <measurement group_id="O2" value="11642.372" spread="11102.059"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax - Peak Plasma Concentration</title>
        <description>Day 1 - Cmax Peak plasma concentration</description>
        <time_frame>pre-dose and 1, 2, 2.5, 2.75, 3, 3.25, 3.5, 3.75, 4, 4.25, 4.5, 4.75, 5, 7, 9, 12 and 24 hours post-dose.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Subjects With Moderate Hepatic Impairment</title>
            <description>This was an open-label, multiple-dose, single-centre study in 2 groups of subjects: subjects with moderate hepatic impairment and healthy controls
BIA 2-093</description>
          </group>
          <group group_id="O2">
            <title>Subjects - Healthy Controls</title>
            <description>This was an open-label, multiple-dose, single-centre study in 2 groups of subjects: subjects with moderate hepatic impairment and healthy controls
BIA 2-093</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax - Peak Plasma Concentration</title>
          <description>Day 1 - Cmax Peak plasma concentration</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax BIA 2-093</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="477.500" spread="439.131"/>
                    <measurement group_id="O2" value="99.500" spread="55.861"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax BIA 2-194</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16392.778" spread="3508.757"/>
                    <measurement group_id="O2" value="18180.000" spread="1996.970"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax 2-195 Glucoronide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.875" spread="19.045"/>
                    <measurement group_id="O2" value="16.667" spread="15.539"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax Oxcarbazepine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.111" spread="51.948"/>
                    <measurement group_id="O2" value="121.000" spread="63.042"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax BIA 2-093 Glucoronide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.000" spread="2.449"/>
                    <measurement group_id="O2" value="5.000" spread="5.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax BIA 2-194 Glucoronide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1067.000" spread="517.493"/>
                    <measurement group_id="O2" value="1381.125" spread="973.778"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Subjects With Moderate Hepatic Impairment</title>
          <description>This was an open-label, multiple-dose, single-centre study in 2 groups of subjects: subjects with moderate hepatic impairment and healthy controls
BIA 2-093</description>
        </group>
        <group group_id="E2">
          <title>Subjects - Healthy Controls</title>
          <description>This was an open-label, multiple-dose, single-centre study in 2 groups of subjects: subjects with moderate hepatic impairment and healthy controls
BIA 2-093</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (9.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>hepatic encephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (9.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN LOWER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>CHILLS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>SCRATCH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>WOUND</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>BLOOD MAGNESIUM DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>HAEMOPTYSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Head of Clinical Research</name_or_title>
      <organization>Bial – Portela &amp; Cª, S.A.</organization>
      <phone>+351 229 866 100</phone>
      <email>jose.rocha@bial.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

